Patients call for insurance coverage of Celgene’s multiple myeloma drug

Will multip myeloma patients be able to get cheaper and better drugs this year? Now all eyes are on the government’s decision on the health insurance coverage of Revlimid (lenalidomide), a new drug for multiple myeloma.

The assessment is likely to take time since Celgene, the maker of the drug, has recently reduced the price of Revlimid by 52.2 percent to 270,000 won per tablet, while the go...